Supercharged natural killer cells may hold promise for cancer

October 9, 2018 by Kate Wighton, Imperial College London
T cell
Scanning electron micrograph of human T lymphocyte or T cell. Credit: NIAID/NIH

A type of 'supercharged' immune cell could be mass-produced to help fight cancer.

The researchers behind the early-stage finding, from Imperial College London, say the development could mark the next generation of cutting-edge immunotherapy treatments, called CAR-T therapies.

These personalised treatments involve reprogramming immune cells to kill .

NHS England announced on Friday it would be making the first ever CAR therapy licensed for the of lymphoma available to patients on the Cancer Drugs Fund.

In the new study, funded by charity Bloodwise, the research team created a genetically engineered version of a cell called an invariant natural killer T-cell—CAR19-iNKT

Current CAR-T therapies are very expensive (around £300,000 per patient), and tend to be tailor-made for each patient. However, scientists behind the current study say their newer CAR-T therapy has the potential to be ten-fold cheaper, and can be mass-produced to enable one batch to be used on multiple patients.

The new research shows the CAR19-iNKT eliminated all in 60 per cent of mice, with 90 per cent of animals surviving long-term.

The scientists behind the study, published in the journal Cancer Cell, are now considering human trials.

Army of cancer fighters

Professor Anastasios Karadimitris, senior author of the study from Imperial's Department of Medicine, said: "These early findings suggest that a type of immune cell painstakingly engineered in the laboratory to be 'supercharged' holds promise as a new treatment for cancer patients."

CAR (chimeric antigen receptor) therapy is a new type of immunotherapy that involves removing a type of immune cell from a patient's blood, and genetically altering it in the laboratory. This creates a type of supercharged immune cell primed to seek and destroy cancer cells. This new, altered cell is then multiplied in the lab, and an army of these cancer-fighting cells are placed back into the patient.

This approach has been used to create new personalised treatment for leukemia and lymphoma, and resulted in up to one third of patients with no other therapeutic options going into long-term complete remission.

"Cancer researchers and doctors are very excited about this therapy—it means that instead of talking to patients about a hospice, we can offer them a treatment that has a good chance of working," explained Professor Karadimitris who is based at Imperial's Centre for Haematology.

Reprogramming cells

At the moment scientists use a type of immune cell called a T-cell to create CAR treatments called CAR-T.

However, in the new study, the Imperial scientists used a slightly different type of immune cell called iNKT .

Although these cells are much rarer in the body, the researchers found that CAR19-iNKT were more effective than CAR-T at eliminating cancer cells.

When the team used the genetically engineered cells to treat mice with lymphoma (a type of cancer of the lymph system) they found that 90 per cent of animals treated with CAR19-iNKT cells survived long term as compared to 60 per cent survival of mice treated with CAR-T cells.

The researchers were surprised to see the genetically engineered cells could travel to the brain, and also tackle large tumours – raising the possibility the technology could one day be used for brain tumours, as well as other cancers such as prostate and ovarian.

Life-saving treatments

Dr. Alasdair Rankin, Director of Research at the blood cancer research charity Bloodwise, said: "Current CAR-T therapies being approved for use on the NHS are effective for a significant amount of patients, but not everyone responds to these treatments and they are extremely expensive to make.

"This very promising research is in the early stages, but it paints an exciting picture of what the future of this treatment could look like. The possibility of cheaply mass-producing highly effective anti-cancer is in many ways the holy grail of CAR . If successful, it would open up these life-saving treatments to many more patients."

Dr. Antonia Rotolo, first author of the study explained: "The current methods of producing CAR-T cells use the patient's own T cells. However iNKT-cells can be sourced from healthy individuals, and unlike T cells don't need to be matched to the patient. This means CAR19-iNKT cell treatment can be used off-the-shelf"

She added that the next step for the technology is to test it in patients: "Our animal experiments have shown the approach can eliminate cancer cells, but we cannot predict potential side effects—we can only investigate this through patient trials. This is an option we're now exploring."

The team are not yet recruiting for , but for further information on other clinical trials and patient support please visit

Explore further: Making cancer-fighting cells in the lab

More information: Antonia Rotolo et al. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting, Cancer Cell (2018). DOI: 10.1016/j.ccell.2018.08.017

Related Stories

Making cancer-fighting cells in the lab

February 16, 2016
The Shin Kaneko lab found that reprogramming one type of iNKT cells to iPS cells and then differentiating them back results in reprogrammed iNKT cells (re-iNKT cells) that show properties of another type. The ability to make ...

A simple blood test provides personalised therapy for cancer patients

September 6, 2018
Researchers have developed a simple blood test that can select cancer patients where therapies that use the body's own immune system (immunotherapies) are more likely to be effective.

Engineered cell therapy rejected for aggressive adult lymphoma on NHS in England

September 19, 2018
A cancer immunotherapy has been provisionally rejected as a treatment for some adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.

Often-overlooked natural killer cells may be key to cancer immunotherapy

September 10, 2018
Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work. This research, published in the prestigious Journal of Clinical Investigation, ...

CAR-T therapy works for some blood cancers, but can we make it work for brain tumours?

July 26, 2018
A powerful new anti-cancer therapy, called CAR-T, has shown great promise in treating blood cancers. Last year, the Food and Drug Administration approved the treatment for acute lymphoblastic leukaemia, and the results have ...

New CAR T case study shows promise in acute myeloid leukemia

May 9, 2018
Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune ...

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.